Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FGFR1OP
REST API REST API
Homo sapiens
FGFR1OP is differentially expressed in 335 experiments: 144 organism parts: prostate, testis, ... (142 more);, 227 disease states: normal, control, ... (225 more);, 106 cell types 450 cell lines 48 compound treatments and 80 other conditions.
Synonyms FOP
Orthologs FGFR1OP (Gallus gallus)   fgfr1op (Danio rerio)   FGFR1OP (Bos taurus)   Fgfr1op (Mus musculus)   FR1OP_RAT (Rattus norvegicus)   fgfr1op (Xenopus laevis)   FGFR1OP (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, cytoskeleton, cytoplasm, negative regulation of protein kinase activity, positive regulation of cell proliferation, mitotic cell cycle, centrosome, protein kinase binding, nucleus, G2/M transition of mitotic cell cycle, perinuclear region of cytoplasm, protein homodimerization activity, positive regulation of cell growth, positive regulation of cell migration, microtubule anchoring, protein tyrosine kinase inhibitor activity, negative regulation of protein tyrosine kinase activity
InterPro Term LisH_dimerisation, FOP_dimerisation-dom_N
UniProt Accession O95684, E7ET71
Search EB-eye ENSG00000213066
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-1577, E-GEOD-2549, ... (31 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (44 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
1
3
E-GEOD-20081, E-GEOD-19639, E-GEOD-3529, E-GEOD-5823
SNU1
2
E-GEOD-15460, E-MTAB-37
BT-474
2
E-GEOD-3529, E-GEOD-5823
BT20
2
E-MTAB-37, E-MTAB-62
MDA468
2
E-MEXP-440, E-MTAB-62
444 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (52 experiments)

Factor Value U/D Experiments
embryonic stem cell
2
E-MEXP-930, E-GEOD-26672
CD4 positive T-cell
1
E-GEOD-6338
CXCR5(-)ICOS(-/lo) CD4 T cell
1
E-MEXP-750
hMOF knock-down
1
E-GEOD-20193
eNK cell
1
E-GEOD-20499
CD34+
1
E-AFMX-5
100 more value(s).


Disease state

studied in E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (67 experiments)

Factor Value U/D Experiments
glioblastoma
4
E-GEOD-4290, E-MTAB-37, E-GEOD-6014, E-GEOD-4412
lung adenocarcinoma
4
E-MTAB-37, E-GEOD-2514, E-MTAB-62, E-MEXP-231
control
1
4
E-GEOD-21912, E-GEOD-8121, E-GEOD-16363, E-GEOD-20295, E-GEOD-20602 ... (5 experiments)
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
acute lymphoblastic leukemia
2
E-GEOD-96, E-MTAB-62
221 more value(s).


Compound treatment

studied in E-GEOD-7400, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (29 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-941, E-MEXP-1335
mercaptopurine, methotrexate
1
E-GEOD-412
poly(I:C)
1
E-MEXP-1230
MIG control
1
E-GEOD-15811
mannitol
1
E-GEOD-6400
unknown
1
E-GEOD-7307
42 more value(s).


Age at onset

studied in E-GEOD-21521

Factor Value U/D Experiments
LT6
1
1
E-GEOD-21521
GTE6
1
1
E-GEOD-21521


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21374, ... (10 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-MEXP-2280, ... (9 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-1643

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-GEOD-7011, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-MEXP-421, ... (12 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-MEXP-1273, E-GEOD-20505, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (41 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-MEXP-1082, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, E-MEXP-1403

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (6 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, ... (7 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Tissue
studied in E-GEOD-30573

Transfection
studied in E-GEOD-14680

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-12198

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments 00 005
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-1561, E-GEOD-4922 ... (5 experiments)

Vehicle
studied in E-GEOD-5258

Processing time: 0.527 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM